A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 79, Issue 1, 2013, Pages 27-32

  Bertino, Erin M ^a   Bekaii Saab, Tanios ^a   Fernandez, Soledad ^b   Diasio, Robert B ^c   Karim, Nagla A ^d   Otterson, Gregory A ^a   Villalona Calero, Miguel A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Capecitabine; Dihydropyrimidine deficiency; Non small cell lung cancer

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CAPECITABINE; CARBOPLATIN; COLONY STIMULATING FACTOR; DEXAMETHASONE; DOCETAXEL; ERYTHROPOIETIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UFT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BLOOD; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SCREENING; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84871052576     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.013     Document Type: Article

References (24)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. Hotta K., Fujiwara Y., Matsuo K., Suzuki T., Kiura K., Tabata M., et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007, 109:939-948.
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
4. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
5. Okamoto I., Yoshioka H., Morita S., Ando M., Takeda K., Seto T., et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010, 28:5240-5246.
6. Shin S.J., Kim H., Baek J.H., Ahn J.J., Jegal Y., Seo K.W., et al. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma. Lung Cancer 2008, 60:83-91.
7. Saito J., Nakai Y., Saijo Y., Nukiwa T., Koinumaru S., Matsuura Y., et al. A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC). Lung Cancer 2001, 31:285-293.
8. Ichinose Y., Yosimori K., Yoneda S., Kuba M., Kudoh S., Niitani H. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma: a multiinstitutional phase II trial. For the Japan UFT Lung Cancer Study Group. Cancer 2000, 88:318-323.
9. Takayama K., Kawasaki M., Ninomiya K., Motohiro A., Fujita M., Watanabe K., et al. Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer. Respirology 2008, 13:103-107.
10. Shiroyama T., Komuta K., Imamura F., Hirashima T., Kijima T., Tachibana I., et al. Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer 2011, 74:85-88.
11. Takiguchi Y., Tada Y., Gemma A., Kudoh S., Hino M., Yoshimori K., et al. Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. Lung Cancer 2010, 68:409-414.
12. Akie K., Oizumi S., Ogura S., Shinagawa N., Kikuchi E., Fukumoto S., et al. Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601. Oncology 2011, 81:84-90.
13. Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557.
14. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34:1274-1281.
15. Sawada N., Ishikawa T., Fukase Y., Nishida M., Yoshikubo T., Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998, 4:1013-1019.
16. Nadella P., Shapiro C., Otterson G.A., Hauger M., Erdal S., Kraut E., et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002, 20:2616-2623.
17. Kindwall-Keller T., Otterson G.A., Young D., Neki A., Criswell T., Nuovo G., et al. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2005, 11:1870-1876.
18. Harris B.E., Carpenter J.T., Diasio R.B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991, 68:499-501.
19. Lu Z., Zhang R., Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53:5433-5438.
20. Hainsworth J.D., Burris H.A., Erland J.B., Thomas M., Greco F.A. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998, 16:2164-2168.
21. Johnson M.R., Yan J., Shao L., Albin N., Diasio R.B. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B: Biomed Sci Appl 1997, 696:183-191.
22. Mattison L.K., Fourie J., Desmond R.A., Modak A., Saif M.W., Diasio R.B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006, 12:5491-5495.
23. Han J.Y., Lee D.H., Kim H.Y., Hong E.K., Yoon S.M., Chun J.H., et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer 2003, 98:1918-1924.
24. Han J.Y., Hong E.K., Lee S.Y., Yoon S.M., Lee D.H., Lee J.S. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 2005, 58:650-654.